Qinghai Spring Medicinal Resources Technology Co Ltd (600381) - Net Assets

Latest as of March 2026: CN¥983.66 Million CNY ≈ $143.94 Million USD

Based on the latest financial reports, Qinghai Spring Medicinal Resources Technology Co Ltd (600381) has net assets worth CN¥983.66 Million CNY (≈ $143.94 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.02 Billion ≈ $149.28 Million USD) and total liabilities (CN¥36.47 Million ≈ $5.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600381 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥983.66 Million
% of Total Assets	96.43%
Annual Growth Rate	9.16%
5-Year Change	-45.09%
10-Year Change	-50.11%
Growth Volatility	159.23

Qinghai Spring Medicinal Resources Technology Co Ltd - Net Assets Trend (1998–2025)

This chart illustrates how Qinghai Spring Medicinal Resources Technology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 600381 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Qinghai Spring Medicinal Resources Technology Co Ltd (1998–2025)

The table below shows the annual net assets of Qinghai Spring Medicinal Resources Technology Co Ltd from 1998 to 2025. For live valuation and market cap data, see Qinghai Spring Medicinal Resources Techn market cap and net worth.

Year	Net Assets	Change
2025-12-31	CN¥999.61 Million ≈ $146.27 Million	-3.54%
2024-12-31	CN¥1.04 Billion ≈ $151.64 Million	-18.23%
2023-12-31	CN¥1.27 Billion ≈ $185.45 Million	-17.33%
2022-12-31	CN¥1.53 Billion ≈ $224.32 Million	-15.80%
2021-12-31	CN¥1.82 Billion ≈ $266.39 Million	-12.02%
2020-12-31	CN¥2.07 Billion ≈ $302.77 Million	-13.38%
2019-12-31	CN¥2.39 Billion ≈ $349.53 Million	+0.24%
2018-12-31	CN¥2.38 Billion ≈ $348.68 Million	+2.71%
2017-12-31	CN¥2.32 Billion ≈ $339.48 Million	+15.78%
2016-12-31	CN¥2.00 Billion ≈ $293.22 Million	+13.96%
2015-12-31	CN¥1.76 Billion ≈ $257.31 Million	+470.08%
2014-12-31	CN¥308.44 Million ≈ $45.13 Million	+516.46%
2013-12-31	CN¥50.03 Million ≈ $7.32 Million	-97.68%
2012-12-31	CN¥2.15 Billion ≈ $314.92 Million	-7.16%
2011-12-31	CN¥2.32 Billion ≈ $339.20 Million	+2096.55%
2010-12-31	CN¥-116.10 Million ≈ $-16.99 Million	+34.82%
2009-12-31	CN¥-178.12 Million ≈ $-26.06 Million	+22.83%
2008-12-31	CN¥-230.81 Million ≈ $-33.78 Million	+36.31%
2007-12-31	CN¥-362.40 Million ≈ $-53.03 Million	+15.64%
2006-12-31	CN¥-429.60 Million ≈ $-62.86 Million	-231.07%
2005-12-31	CN¥327.77 Million ≈ $47.96 Million	-33.07%
2004-12-31	CN¥489.71 Million ≈ $71.66 Million	+25.04%
2003-12-31	CN¥391.64 Million ≈ $57.31 Million	+11.33%
2002-12-31	CN¥351.79 Million ≈ $51.48 Million	+5.33%
2001-12-31	CN¥333.98 Million ≈ $48.87 Million	+183.52%
2000-12-31	CN¥117.80 Million ≈ $17.24 Million	+3.90%
1999-12-31	CN¥113.38 Million ≈ $16.59 Million	+20.79%
1998-12-31	CN¥93.87 Million ≈ $13.74 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Qinghai Spring Medicinal Resources Technology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 9816955477.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥97.96 Million	9.84%
Other Components	CN¥897.27 Million	90.16%
Total Equity	CN¥995.23 Million	100.00%

Qinghai Spring Medicinal Resources Technology Co Ltd Competitors by Market Cap

The table below lists competitors of Qinghai Spring Medicinal Resources Technology Co Ltd ranked by their market capitalization.

Company	Market Cap
Changzhou Shenli Electrical Machine Incorporated Co SHG:603819	$444.14 Million
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A SHE:002864	$444.17 Million
Prisma Properties ST:PRISMA	$444.40 Million
Albaraka Turk Katilim Bankasi AS IS:ALBRK	$444.59 Million
STL Technology Co Ltd TWO:4931	$444.12 Million
Man Industries (India) Limited NSE:MANINDS	$444.09 Million
Shenzhen Hifuture Electric SHE:002168	$444.07 Million
Doubledown Interactive Co Ltd NASDAQ:DDI	$444.00 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Qinghai Spring Medicinal Resources Technology Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 1,032,551,890 to 995,231,528, a change of -37,320,362 (-3.6%).
Net loss of 37,320,363 reduced equity.
Other comprehensive income decreased equity by 106,583,374.
Other factors increased equity by 106,583,375.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-37.32 Million	-3.75%
Other Comprehensive Income	CN¥-106.58 Million	-10.71%
Other Changes	CN¥106.58 Million	+10.71%
Total Change	CN¥-	-3.61%

Book Value vs Market Value Analysis

This analysis compares Qinghai Spring Medicinal Resources Technology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.05x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 6.87x to 3.05x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1998-12-31	CN¥0.75	CN¥5.17	x
1999-12-31	CN¥0.88	CN¥5.17	x
2000-12-31	CN¥0.90	CN¥5.17	x
2001-12-31	CN¥2.63	CN¥5.17	x
2002-12-31	CN¥2.72	CN¥5.17	x
2003-12-31	CN¥2.94	CN¥5.17	x
2004-12-31	CN¥3.08	CN¥5.17	x
2005-12-31	CN¥1.78	CN¥5.17	x
2006-12-31	CN¥-3.50	CN¥5.17	x
2007-12-31	CN¥-3.03	CN¥5.17	x
2008-12-31	CN¥-2.16	CN¥5.17	x
2009-12-31	CN¥-1.75	CN¥5.17	x
2010-12-31	CN¥-0.81	CN¥5.17	x
2011-12-31	CN¥7.52	CN¥5.17	x
2012-12-31	CN¥50.25	CN¥5.17	x
2013-12-31	CN¥-0.16	CN¥5.17	x
2014-12-31	CN¥0.50	CN¥5.17	x
2015-12-31	CN¥2.75	CN¥5.17	x
2016-12-31	CN¥3.18	CN¥5.17	x
2017-12-31	CN¥3.95	CN¥5.17	x
2018-12-31	CN¥4.17	CN¥5.17	x
2019-12-31	CN¥4.11	CN¥5.17	x
2020-12-31	CN¥3.50	CN¥5.17	x
2021-12-31	CN¥3.08	CN¥5.17	x
2022-12-31	CN¥2.61	CN¥5.17	x
2023-12-31	CN¥2.17	CN¥5.17	x
2024-12-31	CN¥1.77	CN¥5.17	x
2025-12-31	CN¥1.70	CN¥5.17	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Qinghai Spring Medicinal Resources Technology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -3.75%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -10.87%
• Asset Turnover: 0.33x
• Equity Multiplier: 1.05x
Recent ROE (-3.75%) is below the historical average (4.33%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1998	10.36%	7.49%	0.61x	2.27x	CN¥337.40K
1999	14.17%	16.70%	0.38x	2.21x	CN¥4.56 Million
2000	15.65%	16.92%	0.34x	2.71x	CN¥6.37 Million
2001	5.93%	13.62%	0.24x	1.82x	CN¥-13.35 Million
2002	6.09%	6.81%	0.39x	2.26x	CN¥-13.24 Million
2003	7.52%	6.22%	0.38x	3.22x	CN¥-9.10 Million
2004	4.91%	1.90%	0.58x	4.46x	CN¥-19.55 Million
2005	-72.08%	-27.40%	0.43x	6.17x	CN¥-182.59 Million
2006	0.00%	-646.14%	0.20x	0.00x	CN¥-514.68 Million
2007	0.00%	528.31%	0.03x	0.00x	CN¥89.36 Million
2008	0.00%	287.43%	0.11x	0.00x	CN¥144.01 Million
2009	0.00%	97.04%	0.15x	0.00x	CN¥73.20 Million
2010	0.00%	87.31%	0.07x	0.00x	CN¥68.54 Million
2011	4.80%	38.78%	0.06x	2.04x	CN¥-100.26 Million
2012	16.37%	22.54%	0.32x	2.25x	CN¥114.60 Million
2013	0.00%	15.74%	1.44x	0.00x	CN¥340.57 Million
2014	150.44%	17.70%	1.44x	5.91x	CN¥340.94 Million
2015	20.38%	25.51%	0.66x	1.20x	CN¥182.10 Million
2016	12.25%	34.59%	0.32x	1.11x	CN¥44.99 Million
2017	13.41%	65.92%	0.19x	1.05x	CN¥79.01 Million
2018	2.88%	20.55%	0.14x	1.02x	CN¥-169.54 Million
2019	0.24%	2.48%	0.10x	1.01x	CN¥-233.06 Million
2020	-15.44%	-257.14%	0.06x	1.07x	CN¥-526.45 Million
2021	-13.66%	-194.59%	0.07x	1.02x	CN¥-430.66 Million
2022	-18.76%	-179.52%	0.10x	1.02x	CN¥-440.84 Million
2023	-21.17%	-125.24%	0.16x	1.07x	CN¥-394.37 Million
2024	-19.25%	-73.55%	0.23x	1.13x	CN¥-302.02 Million
2025	-3.75%	-10.87%	0.33x	1.05x	CN¥-136.84 Million

Industry Comparison

This section compares Qinghai Spring Medicinal Resources Technology Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $6,315,236,927
Average return on equity (ROE) among peers: 5.41%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Qinghai Spring Medicinal Resources Technology Co Ltd (600381)	CN¥983.66 Million	10.36%	0.04x	$444.13 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$692.59 Million	2.04%	3.57x	$596.77 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$44.35 Million	17.35%	1.49x	$395.07 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$793.34 Million	10.94%	0.24x	$4.56 Billion
Livzon Pharmaceutical Group Inc (000513)	$546.67 Million	0.00%	0.46x	$2.64 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.51 Billion
Yunnan Baiyao Group Co Ltd (000538)	$38.53 Billion	7.79%	0.38x	$12.75 Billion
Hainan Haiyao Co Ltd (000566)	$2.54 Billion	7.70%	0.92x	$791.65 Million
Tus Pharmaceutical Group Co Ltd (000590)	$278.65 Million	-21.41%	1.49x	$358.83 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$999.14 Million	3.56%	1.59x	$981.49 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$17.58 Billion	14.75%	0.13x	$3.08 Billion

About Qinghai Spring Medicinal Resources Technology Co Ltd

SHG:600381 China Drug Manufacturers - Specialty & Generic

Market Cap

$444.13 Million

CN¥3.04 Billion CNY

Market Cap Rank

#13198 Global

#4050 in China

Share Price

CN¥5.17

Change (1 day)

+5.08%

52-Week Range

CN¥2.61 - CN¥5.58

All Time High

CN¥24.91